Pulse Biosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
759.00
1,001.00
1,310
Gross Income
759.00
1,001.00
1,310
SG&A Expense
8,827.00
24,813.00
36,653
EBIT
9,586.00
25,814.00
37,963
Pretax Income
9,518.00
25,567.00
37,545
Consolidated Net Income
9,518.00
25,567.00
37,545
Net Income
9,518.00
25,567.00
37,545
Net Income After Extraordinaries
9,518.00
25,567.00
37,545
Net Income Available to Common
9,518.00
25,567.00
37,545
EPS (Basic)
0.86
1.73
2.20
Basic Shares Outstanding
11,009.00
14,754.00
17,078
EPS (Diluted)
0.86
1.73
2.20
Diluted Shares Outstanding
11,009.00
14,754.00
17,078
EBITDA
8,827.00
24,813.00
36,653
Non-Operating Interest Income
68.00
247.00
446

About Pulse Biosciences

View Profile
Address
3957 Point Eden Way
Hayward California 94545
United States
Employees -
Website http://www.pulsebiosciences.com
Updated 07/08/2019
Pulse Biosciences, Inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary Nano-Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells.